Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the Year’ at the recent Biotech and Money 2017 Awards. The award recognises both Microbiotica’s potential in the microbiome sector and its achievements to date as the newest spin-out […]
Cambridge, UK, 9 August 2017 – Microbiotica, a leading player in microbiome-based therapeutics, is delighted to be announced that it has been selected as a finalist in the ‘Best Start-up Biotech Company’ category of the OBN Awards 2017. Being selected for the shortlist recognises Microbiotica’s commercial potential in the fast growing microbiome space, reflecting its innovative […]
Cambridge, UK, 13 July 2017 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to announce that it was voted as the winner of the Summer 2017 BioNewsRound Award at the One Nucleus event held ahead of the Annual On Helix conference in Cambridge. Microbiotica won the award based on the prospects for the company, […]
Cambridge, UK, 26 June 2017 Microbiotica, a leading player in microbiome-based therapeutics, is delighted to announce that it has been shortlisted for the ‘Life Science Spin-out of the Year’ category of the Biotech and Money 2017 Awards. Microbiotica was selected as a shortlisted finalist for its success as the newest spin-out company from the UK’s […]
27-29 June 2017, Boston Cambridge, UK, 20 June 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley will present at this year’s Microbiome Drug Development Summit, 27-29 June in Boston. Dr Lawley’s talk ‘Culturing the “unculturable” to harness the therapeutic potential of the human intestinal microbiome’ […]
Microbiotica, the spin-out company from the UK’s Wellcome Trust Sanger Institute (Sanger Institute), is pleased to announce the appointment of Dr John Shields as a non-executive director representing the Sanger Institute. Dr Shields has extensive operational and investment experience in the biotechnology sector and is currently a member of the Sanger Institute Translation Committee, the […]
Based on ground-breaking research at the Wellcome Trust Sanger Institute into the role of the human microbiome in disease Goal is to create the world’s leading company focused on microbiome biology and its use in medicine Cambridge Innovation Capital and IP Group co-lead £8m funding round Cambridge Innovation Capital plc (“CIC”), a Cambridge-based investor in […]
Find us on LinkedIn
info@microbiotica.com